Tuberculosis and Respiratory Diseases

  • 제70권5호
  • /
  • Pages.384-389
  • /
  • 2011
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

지속성 무스카린 대항제(LAMA)의 안전성

Issues on Safety of Long-Acting Muscarinic Antagonist

  • 이양덕 (을지대학교 의과대학 내과학교실) ;
  • 조용선 (을지대학교 의과대학 내과학교실) ;
  • 한민수 (을지대학교 의과대학 내과학교실)
  • Lee, Yang-Deok (Department of Internal Medicine, Eulji University School of Medicine) ;
  • Cho, Yong-Seon (Department of Internal Medicine, Eulji University School of Medicine) ;
  • Han, Min-Soo (Department of Internal Medicine, Eulji University School of Medicine)
  • 투고 : 2011.03.08
  • 심사 : 2011.04.10
  • 발행 : 2011.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The prevention of and the controlling of symptoms, reductions in the frequency of exacerbations, and disease severity are central to the pharmacologic therapy of chronic obstructive pulmonary disease (COPD). COPD patients are inclined to be older, have more comorbidities, and use polypharmacy as a result. Long-acting inhaled muscarinic antagonists (LAMAs) is a preferred treatment modality. However, the cardiovascular (CV) safety of anti-cholinergics, including LAMA, has been an issue. In contrast, the results of the UPLIFT trial and a pooled analysis of data from 30 trials of tiotropium illustrates the association of tiotropium with reductions in the risk of all cause mortality, CV mortality and CV events. And, the UPLIFT trial provides clues regarding the additive advantages of tiotropium in COPD patients who already are using long-acting inhaled ${\beta}_2$ agonists and inhaled corticosteroids. Following the contribution of tiotropium as a first LAMA, new LAMAs such as aclidinium and glycopyrrolate (NVA-237) seem to be emerging.

키워드

참고문헌

  1. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, updated 2010 [Internet]. Bethesda, MD: GOLD; c2010 [cited 2011 May 13]. Available from: http://www.goldcopd.com/download.asp?intId=617.
  2. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010;16:97-105. https://doi.org/10.1097/MCP.0b013e328335df1e
  3. Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2010;19:257-64. https://doi.org/10.1517/13543780903505084
  4. Kim SJ, Kim MS, Lee SH, Kim YK, Moon HS, Park SH, et al. A comparison of tiotropium 18 microgram, once daily and ipratropium 40 microgram, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease. Tuberc Respir Dis 2005;58:498-506. https://doi.org/10.4046/trd.2005.58.5.498
  5. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis [Internet]. Silver Spring, MD: US Food and Drug Administration; 2008. [Cited 2011 May 13]. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf.
  6. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90. https://doi.org/10.7326/0003-4819-149-6-200809160-00004
  7. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50. https://doi.org/10.1001/jama.300.12.1439
  8. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54. https://doi.org/10.1056/NEJMoa0805800
  9. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30. https://doi.org/10.1378/chest.09-0011
  10. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-- the FDA's conclusions. N Engl J Med 2010;363:1097-9. https://doi.org/10.1056/NEJMp1008502
  11. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63S-6S. https://doi.org/10.1378/chest.117.2_suppl.63S
  12. Valente S, Pasciuto G, Bernabei R, Corbo GM. Do we need different treatments for very elderly COPD patients? Respiration 2010;80:357-68. https://doi.org/10.1159/000320221
  13. Spiriva Handihaler package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2010.
  14. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703. https://doi.org/10.1378/chest.130.6.1695
  15. Pedone C, Incalzi RA. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:185. https://doi.org/10.1056/NEJMc082265
  16. Chang ET. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:185. https://doi.org/10.1056/NEJMc082265
  17. O'Connor AB. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:185-6. https://doi.org/10.1056/NEJMc082265
  18. Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:186.
  19. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009;169:1403-10. https://doi.org/10.1001/archinternmed.2009.233
  20. Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005;18:273-82. https://doi.org/10.1089/jam.2005.18.273
  21. Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2007;2:559-65.
  22. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009;330:660-8. https://doi.org/10.1124/jpet.109.152470
  23. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005;128:1974-9. https://doi.org/10.1378/chest.128.4.1974
  24. Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998;274:L970-9.